Sodium Glucose Co-Transporter 2 inhibitors (SGLT2i): not just for diabetes

Helps heart failure and aging, too. PREMIUM CONTENT subscriber access

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are antihyperglycemic agents acting on the SGLT-2 proteins expressed in the proximal convoluted tubules.  These drugs exert their effect by preventing the reabsorption of filtered glucose from the tubular lumen.

Heart failure is often complicated with Cardiorenal syndrome, making diuretic use, tricky to dose. So it is good news to learn that the diabetes drug, SGLT2i, improves solute excretion without loss of free water.

https://www.ahajournals.org/doi/10.1161/CIR.0000000000000664#d1e657

SGLT2i can also act as senolytic agents: mice models show amelioration of diabetes, arteriosclerosis, premature aging, and frailty — prolonging the life span - with use of these drugs.